Literature DB >> 28391521

Generating pulsatility by pump speed modulation with continuous-flow total artificial heart in awake calves.

Kiyotaka Fukamachi1, Jamshid H Karimov2, Gengo Sunagawa3, David J Horvath3,4, Nicole Byram3, Barry D Kuban5, Raymond Dessoffy3, Shiva Sale6, Leonard A R Golding3, Nader Moazami3,7.   

Abstract

The purpose of this study was to evaluate the effects of sinusoidal pump speed modulation of the Cleveland Clinic continuous-flow total artificial heart (CFTAH) on hemodynamics and pump flow in an awake chronic calf model. The sinusoidal pump speed modulations, performed on the day of elective sacrifice, were set at ±15 and ± 25% of mean pump speed at 80 bpm in four awake calves with a CFTAH. The systemic and pulmonary arterial pulse pressures increased to 12.0 and 12.3 mmHg (±15% modulation) and to 15.9 and 15.7 mmHg (±25% modulation), respectively. The pulsatility index and surplus hemodynamic energy significantly increased, respectively, to 1.05 and 1346 ergs/cm at ±15% speed modulation and to 1.51 and 3381 ergs/cm at ±25% speed modulation. This study showed that it is feasible to generate pressure pulsatility with pump speed modulation; the platform is suitable for evaluating the physiologic impact of pulsatility and allows determination of the best speed modulations in terms of magnitude, frequency, and profiles.

Entities:  

Keywords:  Heart-assist devices; Hemodynamics; Implants, experimental; Pulsatile flow; Waveform

Mesh:

Year:  2017        PMID: 28391521      PMCID: PMC5632582          DOI: 10.1007/s10047-017-0958-5

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  14 in total

1.  Functional and haemodynamic recovery after implantation of continuous-flow left ventricular assist devices in comparison with pulsatile left ventricular assist devices in patients with end-stage heart failure.

Authors:  Ralph V Pruijsten; Sjoukje I Lok; Hans H Kirkels; Corinne Klöpping; Jaap R Lahpor; Nicolaas de Jonge
Journal:  Eur J Heart Fail       Date:  2012-01-30       Impact factor: 15.534

2.  Precise quantification of pressure flow waveforms of a pulsatile ventricular assist device.

Authors:  Akif Undar; Conrad M Zapanta; John D Reibson; Matthew Souba; Branka Lukic; William J Weiss; Alan J Snyder; Allen R Kunselman; William S Pierce; Gerson Rosenberg; John L Myers
Journal:  ASAIO J       Date:  2005 Jan-Feb       Impact factor: 2.872

Review 3.  Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory?

Authors:  Rodger Loutzenhiser; Karen A Griffin; Anil K Bidani
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-01       Impact factor: 2.894

4.  First report of 90-day support of 2 calves with a continuous-flow total artificial heart.

Authors:  Jamshid H Karimov; Nader Moazami; Mariko Kobayashi; Shiva Sale; Kimberly Such; Nicole Byram; Gengo Sunagawa; David Horvath; Shengqiang Gao; Barry Kuban; Leonard A R Golding; Kiyotaka Fukamachi
Journal:  J Thorac Cardiovasc Surg       Date:  2015-06-18       Impact factor: 5.209

Review 5.  Pulsatile and nonpulsatile perfusion: the continuing controversy.

Authors:  P Hornick; K Taylor
Journal:  J Cardiothorac Vasc Anesth       Date:  1997-05       Impact factor: 2.628

6.  Physiopathological studies of nonpulsatile blood flow in chronic models.

Authors:  I Yada; L R Golding; H Harasaki; G Jacobs; S Koike; R Yozu; N Sato; L K Fujimoto; J Snow; E Olsen
Journal:  Trans Am Soc Artif Intern Organs       Date:  1983

7.  Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II.

Authors:  Omar Wever-Pinzon; Craig H Selzman; Stavros G Drakos; Abdulfattah Saidi; Gregory J Stoddard; Edward M Gilbert; Mohamed Labedi; Bruce B Reid; Erin S Davis; Abdallah G Kfoury; Dean Y Li; Josef Stehlik; Feras Bader
Journal:  Circ Heart Fail       Date:  2013-03-11       Impact factor: 8.790

8.  An innovative, sensorless, pulsatile, continuous-flow total artificial heart: device design and initial in vitro study.

Authors:  Kiyotaka Fukamachi; David J Horvath; Alex L Massiello; Hideyuki Fumoto; Tetsuya Horai; Santosh Rao; Leonard A R Golding
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

9.  In vivo acute performance of the Cleveland Clinic self-regulating, continuous-flow total artificial heart.

Authors:  Hideyuki Fumoto; David J Horvath; Santosh Rao; Alex L Massiello; Tetsuya Horai; Tohru Takaseya; Yoko Arakawa; Nicole Mielke; Ji-Feng Chen; Raymond Dessoffy; Kiyotaka Fukamachi; Leonard A R Golding
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

10.  Clinical outcome and bridge to transplant rate of left ventricular assist device recipient patients: comparison between continuous-flow and pulsatile-flow devices.

Authors:  Andrea Garatti; Giuseppe Bruschi; Tiziano Colombo; Claudio Russo; Marco Lanfranconi; Filippo Milazzo; Maria Frigerio; Ettore Vitali
Journal:  Eur J Cardiothorac Surg       Date:  2008-03-28       Impact factor: 4.191

View more
  3 in total

Review 1.  The ongoing quest for the first total artificial heart as destination therapy.

Authors:  Annemijn Vis; Maziar Arfaee; Husain Khambati; Mark S Slaughter; Jan F Gummert; Johannes T B Overvelde; Jolanda Kluin
Journal:  Nat Rev Cardiol       Date:  2022-06-06       Impact factor: 32.419

2.  Simulated Performance of the Cleveland Clinic Continuous-Flow Total Artificial Heart Using the Virtual Mock Loop.

Authors:  Takuma Miyamoto; David J Horvath; Dennis W Horvath; Jamshid H Karimov; Nicole Byram; Barry D Kuban; Kiyotaka Fukamachi
Journal:  ASAIO J       Date:  2019-08       Impact factor: 2.872

3.  Pulsatility hemodynamics during speed modulation of continuous-flow total artificial heart in a chronic in vivo model.

Authors:  Taiyo Kuroda; Takuma Miyamoto; Chihiro Miyagi; Anthony R Polakowski; Christine R Flick; Barry D Kuban; George B Voros; Kimberly Such; Kiyotaka Fukamachi; Jamshid H Karimov
Journal:  Artif Organs       Date:  2022-03-31       Impact factor: 2.663

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.